Welcome to our dedicated page for Artivion SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
An AORT shareholder filed a Rule 144 notice to sell up to 4,572 shares of common stock through Fidelity Brokerage Services on the NYSE around 12/08/2025. The filing lists an aggregate market value of $203,081.38 for this planned sale, compared with 47,374,939 common shares outstanding for the issuer. The seller acquired these 4,572 shares as restricted stock vesting from the issuer on 12/05/2025, treated as compensation.
Over the prior three months, the same seller reported additional open-market sales of the issuer’s common stock: 1,789 shares on 11/10/2025 for $79,823.21, 3,482 shares on 11/13/2025 for $159,678.60, and 6,000 shares on 11/17/2025 for $274,382.11. By signing, the seller represents they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. reported an insider stock transaction by its President & CEO, James P. Mackin. On December 3, 2025, he exercised stock options to acquire 30,921 shares of Artivion common stock at an exercise price of $29.62 per share, then sold the same 30,921 shares in the open market at a weighted average price of approximately $45.461 per share.
The option exercise and sale were conducted under a Rule 10b5-1 trading plan adopted on September 2, 2025. After these transactions, he directly owns 800,993 shares of Artivion common stock. The reported stock option, originally granted on March 5, 2020 with an expiration date of March 5, 2026, is now fully exercised and shows 0 options remaining.
Artivion, Inc. executive Jean F. Holloway, the company’s SVP and General Counsel, reported open-market sales of company stock. On 12/03/2025, she sold 2,048 shares of Artivion common stock at a price of $45.3 per share and, in a separate transaction the same day, sold an additional 5,267 shares at $45.3 per share.
Following these transactions, Holloway beneficially owns 156,093 shares of Artivion common stock directly. The filing is a standard Form 4 disclosure of insider trading activity required for company officers.
Artivion, Inc. (AORT) reported an insider stock transaction by its President & CEO. On 12/02/2025, the executive exercised stock options to buy 30,921 shares of common stock at an exercise price of $29.62 per share and then sold 30,921 shares of common stock in a separate transaction at a weighted average price of $45.559 per share.
The transactions were executed under a Rule 10b5-1 trading plan adopted on September 2, 2025. Following these moves, the reporting person held 800,993 shares of Artivion common stock in direct ownership.
James Mackin filed a Form 144 notice to sell 30,921 common shares of the issuer through Fidelity Brokerage Services LLC on the NYSE, with 47,374,939 shares outstanding. The shares relate to an option originally granted on 03/05/2019 and acquired on 12/03/2025, with the purchase price paid in cash on the same date. In the past three months, Mackin has sold additional common shares in three transactions, totaling 17,580 shares for gross proceeds of $784,400.26, 34,210 shares for $1,568,812.44, and 30,921 shares for $1,408,736.02. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
An insider of the issuer has filed a Form 144 notice to sell 7,315 shares of common stock through broker Morgan Stanley Smith Barney LLC on the NYSE. The planned sale has an aggregate market value of $331,390.71, while 47,374,939 shares of this class were outstanding at the time of the notice. The shares to be sold were acquired as restricted stock from the issuer on 02/22/2019 and 02/21/2020.
Over the past three months, the same seller, Jean F. Holloway, has already sold several blocks of common stock, including 10,000 shares on 11/11/2025 for gross proceeds of $461,800.00. By signing the notice, the seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Artivion, Inc. executive reports charitable stock gift
An officer of Artivion, Inc., serving as VP and Chief Accounting Officer, filed a Form 4 reporting a gift of 750 shares of Artivion common stock on 12/01/2025. The transaction is coded as a gift and priced at $0, reflecting that the shares were donated rather than sold. After this transaction, the reporting person directly owns 134,630 shares of Artivion common stock. The explanation clarifies that the 750 shares were gifted to a charity.
Artivion insider James Mackin has filed a notice to sell 30,921 shares of common stock of AORT through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of $1,430,714.67. These shares relate to an option originally granted on 03/05/2019 and acquired on 12/02/2025, with the purchase price paid in cash.
Artivion had 47,374,939 shares of common stock outstanding at the time referenced. Over the prior three months, Mackin sold 17,580 shares of common stock on 11/10/2025 for gross proceeds of $784,400.26 and 34,210 shares on 11/13/2025 for gross proceeds of $1,568,812.44. By signing the notice, he represents that he does not know of any undisclosed material adverse information about the company’s current or prospective operations.
Artivion, Inc. (AORT) senior vice president Marshall Stanton reported multiple stock option exercises and related share sales dated 11/21/2025. He exercised options to buy 20,301 shares of common stock at $18.44 per share and another 27,075 shares at $11.03 per share. On the same date, he sold blocks of 14,586 shares at a weighted average price of $44.919, 5,715 shares at $45.346, 18,705 shares at $44.91, and 8,370 shares at $45.345, with each price representing a weighted average within disclosed ranges. After these transactions, he directly owned 44,753 shares of Artivion common stock.
Artivion, Inc. (AORT) senior vice president of Clinical & MD Affairs Marshall Stanton reported insider transactions in company stock. On 11/20/2025, he sold 11,888 shares of common stock at a weighted average price of $44.14 per share, and in separate transactions sold additional shares at weighted average prices of $44.315 and $44.278 per share. The sales were reported as open-market dispositions.
On the same date, Stanton exercised stock options to buy 2,033 shares at an exercise price of $18.44 per share and 1,355 shares at an exercise price of $11.03 per share, then sold the corresponding shares. Following these transactions, he reported beneficial ownership of 44,753 shares of Artivion common stock held directly, along with vested and unexercised stock options covering 20,301 shares at $18.44 and 27,075 shares at $11.03.